Anders Neijber, MD, PhD, MBA
Articles by Anders Neijber, MD, PhD, MBA
Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer
ByE. David Crawford, MD,Neal Shore, MD, FACS,Celestia S. Higano, MD, FACP,Anders Neijber, MD, PhD, MBA,Vladimir Yankov, MD Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.
